Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04269655 · ClinicalTrials.gov registry record · NA
Scripps Digital Diabetes: Cloud-Based Continuous Glucose Monitoring (CB CGM)
A NA study, sponsored by Scripps Whittier Diabetes Institute.
- Terminated
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT04269655: Clinical Trial NA study, sponsored by Scripps Whittier Diabetes Institute.
NCT04269655 is a NA study that was terminated before completion, run by Scripps Whittier Diabetes Institute. The registered enrollment target is 6 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04269655, a NA study, was terminated before completion, sponsored by Scripps Whittier Diabetes Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
Individuals with diabetes in the hospital often experience poor glycemic control, which places them at greater risk for infection, neurological and cardiac complications, mortality, longer lengths of stay, readmissions, and higher healthcare costs. There are few effective interventions for monitoring hospital glucose management therefore the long-term goal of developing Cloud-Based Real-Time Glucose Evaluation and Management System is to provide an effective, real-time continuous glucose monitoring solution necessary for clinical decision-making which can be easily managed for clinical risk 24 hrs/day. The innovative intervention will enable hospital care teams to take immediate steps based on wireless transmission of glucose data from the Dexcom G6 device, sent to a Digital Dashboard, where integration with existing real-world hospital processes can provide immediate prioritization to prevent or correct impending hypoglycemia and severe hyperglycemic events. This randomized controlled trial is defined as a Phase III/IV definitive clinical trial to establish efficacy and effectiveness of this intervention. Aim 1 will assess mean differences of % time in range between intervention and Usual Care groups to find occurrence of glucose levels that are in range at 70-200mg/dL. Aim 2 will apply the same method, using % time above range of \>300mg/dL (severe hyperglycemia) and % time below range \<70mg/dL (hypoglycemia). Poor glycemic control in the hospital is common and given the known consequences of uncontrolled blood sugars during a hospitalization, health systems devote significant resources to developing protocols for improving glucometrics. The likely impact of this innovative research is to have an efficient, and seamless alternative for continually monitoring glucose levels in the hospital. The Digital Dashboard facilitates real-time, remote monitoring of a large volume of patients simultaneously; automatically identifies and prioritizes patients for intervention;
Primary Outcome
Percentage time-in-range (70-200 mg/dL) of interstitial glucose values
Interventions
- DEVICE Cloud-Based Continuous Glucose Monitoring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2020-02-25 |
| Est. Completion | 2020-03-17 |
| Phase | NA |
Why NCT04269655 stopped before completion
NCT04269655 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Cloud-Based Continuous Glucose Monitoring is the first listed.
NCT04269655 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04269655 about?
NCT04269655 is a clinical study titled "Scripps Digital Diabetes: Cloud-Based Continuous Glucose Monitoring (CB CGM)". Individuals with diabetes in the hospital often experience poor glycemic control, which places them at greater risk for infection, neurological and cardiac complications, mortality, longer lengths of stay, readmissions, and higher healthcare costs. There are few effective interventions for monitorin...
What is the current status of trial NCT04269655?
This trial is currently terminated. It is a NA study. The enrollment target is 6 participants. The study started on 2020-02-25. Estimated completion is 2020-03-17.
What interventions are being tested in trial NCT04269655?
The interventions under investigation include: Cloud-Based Continuous Glucose Monitoring (DEVICE).
Who is sponsoring clinical trial NCT04269655?
This trial is sponsored by Scripps Whittier Diabetes Institute, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04269655's enrollment target sits among peer trials
6 1983rd of 2000 higher than 13 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI